Investment

Wilson Sonsini Goodrich & Rosati has invested in genomic sequencing amplification business Bioskryb, co-founded by Stanford faculty member Charles Gawad.

Stanford-StartX's Zinier took its overall funding to $120m in a round that included returning investor Qualcomm Ventures, with the cash to go to international growth and product development.

UW spinout Nicoya has its sight set on product development and business expansion after a series A round featuring UW Student Venture Fund and Wilfrid Laurier University’s Startup Fund.

Treadwell has launched with seed funding from Tio Bioventures to commercialise small molecule cancer drugs based on University Health Network research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Subsidiaries of Astellas and Novartis co-led a series B round that took Harvard's cancer treatment developer's overall funding to $60m.

With hundreds of university venture funds, internal commercialisation vehicles and third-party firms the reality in today’s innovation ecosystem, selecting the nominees and the winner for Investment Unit of the Year is increasingly challenging.

Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.